What leads people with dengue, chikungunya, or other arbovirus infections to need hospital care in the Indian Ocean
Factors Associated With Hospitalization and Severity of Arbovirosis in the Indian Ocean
This project will try to find which clinical, demographic, or laboratory factors make people with dengue, chikungunya, Zika, or other arbovirus infections more likely to be hospitalized or to develop severe disease in the Indian Ocean region.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de la Réunion Academic / other |
| Locations | 1 site (Saint-Pierre) |
| Trial ID | NCT07119086 on ClinicalTrials.gov |
What this trial studies
Patients of all ages presenting to participating hospital departments in Réunion with suspected, probable, or confirmed arbovirosis will be enrolled. The team will collect biological samples and administer standardized questionnaires to gather clinical history, symptoms, exposures, and demographic information. Laboratory testing will determine virus type/serotype and relevant biomarkers while clinical records will capture hospitalization and severity outcomes. Statistical analyses will look for associations between host factors, virus characteristics, and risk of hospitalization or severe disease.
Who should consider this trial
Good fit: People of any age (newborns >2.5 kg, children, adults) seen in participating emergency rooms, inpatient wards, day hospitals, or outpatient clinics with suspected, probable, or confirmed arbovirosis, including newborns of viremic mothers.
Not a fit: People without arbovirus infection, those who do not present to participating hospitals, or individuals whose illness is unrelated to arboviruses may not receive direct benefit from this work.
Why it matters
Potential benefit: If successful, the findings could help clinicians identify patients at higher risk so they can be monitored or treated sooner to prevent severe outcomes.
How similar studies have performed: Similar observational studies of dengue and chikungunya in other settings have identified clinical and demographic risk factors, so this approach builds on existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
1st case : Inclusion Criteria: * Adult, child or newborn \> 2.5kg on day of inclusion. * Use of one of the hospital departments participating in the research, in an emergency room, full hospitalization, day hospitalization or outpatient clinic. * Suspected, probable or biologically confirmed arbovirosis: A suspected case of arbovirosis is defined as : * asymptomatic contact case of a patient with probable or confirmed arbovirosis * symptomatic or non-symptomatic newborns of mothers who were viremic for arbovirosis during pregnancy, or who had probable or confirmed arbovirosis during pregnancy. * In a patient with a history of a stay in an arbovirus circulation zone in the 2 weeks prior to consultation (for imported cases only). * In a patient with compatible clinical symptoms during the epidemic period A probable case of arbovirosis is defined by : * the association of at least 2 objectified or reported signs or biology suggestive of arbovirosis: fever (reported by the patient or family, or documented), headache, rash, myalgias, arthralgias, abdominal pain, bleeding, thrombocytopenia, or * for children under 6: by the reporting (by the family or documented) of a fever on the day of inclusion or in the preceding 7 days, possibly accompanied by pain. A biologically confirmed case of arbovirosis is defined by : \- A positive plasma RT-PCR or urine RT-PCR (Zika virus) Case 2 : - Retrospectively, patients with sufficiently documented definite, probable or suspected arbovirosis, who give oral consent for their data to be collected retrospectively and/or to continue the study follow-up. Exclusion Criteria: 1\. Patient ou titulaire de l'autorité parentale non affiliés ou non bénéficiaires d'un régime de sécurité sociale.
Where this trial is running
Saint-Pierre
- Prct — Saint-Pierre, France (Recruiting)
Study contacts
- Study coordinator: CHU La Réunion DRCI
- Email: melanie.begorre@chu-reunion.fr
- Phone: 0262717885
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.